Completed PHASE2 INTERVENTIONAL NCT00057239

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks

Sponsor: GlaxoSmithKline

Conditions Major Depressive Disorder (MDD)

Interventions Radafaxine

Updated 5 times since 2017 Last updated: Oct 1, 2010 Started: Mar 31, 2003 Primary completion: May 31, 2004 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00057239, this PHASE2 trial focuses on Major Depressive Disorder (MDD) and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brown Deer, United States , Charlotte, United States , Clementon, United States , Cleveland, United States , Conshohocken, United States , Dallas, United States , Dayton, United States , Edwardsville, United States , Eugene, United States , Farmington, United States and 18 more locations